| __timestamp | Blueprint Medicines Corporation | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 24518692 |
| Thursday, January 1, 2015 | 14456000 | 19886580 |
| Friday, January 1, 2016 | 19218000 | 12631689 |
| Sunday, January 1, 2017 | 27986000 | 21977998 |
| Monday, January 1, 2018 | 47928000 | 20759000 |
| Tuesday, January 1, 2019 | 96388000 | 20838000 |
| Wednesday, January 1, 2020 | 157743000 | 121812000 |
| Friday, January 1, 2021 | 195293000 | 152137000 |
| Saturday, January 1, 2022 | 237374000 | 83231000 |
| Sunday, January 1, 2023 | 295141000 | 122706000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Blueprint Medicines Corporation and TG Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, peaking at nearly $295 million in 2023. In contrast, TG Therapeutics experienced a more modest growth of approximately 400%, reaching $123 million in the same year.
This divergence highlights Blueprint's aggressive expansion strategy, while TG Therapeutics maintains a more conservative approach. The data underscores the importance of strategic financial management in the biotech sector, where operational costs can significantly impact a company's competitive edge. As these companies continue to innovate, their financial strategies will be crucial in shaping their future success.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
AbbVie Inc. or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
argenx SE or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG